Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR -mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903).

MLA

Bertino, Erin M., et al. “Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR -Mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903).” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 27, no. 6, Mar. 2021, pp. 1604–11. EBSCOhost, https://doi.org/10.1158/1078-0432.CCR-20-4084.

APA

Bertino, E. M., Gentzler, R. D., Clifford, S., Kolesar, J., Muzikansky, A., Haura, E. B., Piotrowska, Z., Camidge, D. R., Stinchcombe, T. E., Hann, C., Malhotra, J., Villaruz, L. C., Paweletz, C. P., Lau, C. L., Sholl, L., Takebe, N., Moscow, J. A., Shapiro, G. I., Jänne, P. A., & Oxnard, G. R. (2021). Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR -mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903). Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 27(6), 1604–1611. https://doi.org/10.1158/1078-0432.CCR-20-4084

Chicago

Bertino, Erin M, Ryan D Gentzler, Sarah Clifford, Jill Kolesar, Alona Muzikansky, Eric B Haura, Zofia Piotrowska, et al. 2021. “Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR -Mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903).” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 27 (6): 1604–11. doi:10.1158/1078-0432.CCR-20-4084.